COMMENTARY

Promiscuous scaffolds in proteins - non-native, non-additive and non-trivial [version 1; peer review: 1 approved with reservations, 1 not approved]

Sandeep Chakraborty^{1,8}, Bjarni Asgeirsson², Mouparna Dutta³, Anindya S Ghosh³, Masataka Oda⁴, Adela Rendón⁵, Felix Goñi⁵, Jean-Marie Frere⁶, Ravindra Venkatramani⁷, Abhaya M. Dandekar⁸, Basuthkar J. Rao¹

¹Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, 400 005, India

²Science Institute, Department of Biochemistry, University of Iceland, IS-107 Reykjavik, Iceland

³Department of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, 721302, India

⁴Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8514, Japan

⁵Unidad de Bio sica (CSIC, UPV/EHU) and Departamento de Bioquímica, Universidad del Pais Vasco, Bilbao, Spain

⁶Centre for Protein Engineering, Universite de Li ege, Institut de Chimie B6, B-4000 Li ege, Belgium

⁷Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, 400 005, India

⁸Plant Sciences Department, University of California, Davis, CA, 95616, USA

V1 First published: 27 Nov 2013, 2:260
<https://doi.org/10.12688/f1000research.2-260.v1>
 Latest published: 20 Jan 2014, 2:260
<https://doi.org/10.12688/f1000research.2-260.v2>

Abstract

Promiscuity, the ability of an enzyme to catalyze diverse activities using the same active site, sets up the stage for the evolution of complex organisms through gene duplication and specialization. The detection of promiscuous motifs is crucial to understand the physiological relevance of a protein, or for any endeavor that intends to rationally modify these latent capabilities to design new proteins under laboratory conditions. We have established a methodology for identifying catalytic residues based on spatial and electrostatic congruence with known active site configurations. Here, we discuss insights gained in several initiatives using our method on different enzymes.

Open Peer Review

Approval Status **X ? X**

	1	2	3
version 2 (revision) 20 Jan 2014			X view
version 1 27 Nov 2013	X view	? view	

- Neil D. Rawlings**, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK
- Abhinav Nath**, Yale University, New Haven CT, USA
- Christopher Bahl**, University of Washington, Seattle, WA, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Sandeep Chakraborty (sanchak@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2013 Chakraborty S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chakraborty S, Asgeirsson B, Dutta M *et al.* **Promiscuous scaffolds in proteins - non-native, non-additive and non-trivial [version 1; peer review: 1 approved with reservations, 1 not approved]** F1000Research 2013, 2:260 <https://doi.org/10.12688/f1000research.2-260.v1>

First published: 27 Nov 2013, 2:260 <https://doi.org/10.12688/f1000research.2-260.v1>

Primitive life presumably had minimal gene content and a minuscule arsenal of enzymes at its disposal. Unfettered from selection pressures by gene duplication, a few select enzymes gained new advantageous functions¹⁻⁴. Nonetheless, the vestiges of secondary activities under neutral drift⁵ possess the potential to reemerge under changing selection pressures^{6,7}. This ability of an enzyme to catalyze diverse activities using the same active site, termed as promiscuity, is the cornerstone of the evolution of complex organisms from pristine life⁸. In the human context, compound promiscuity plays a major role in drug discovery, and in the therapeutic efficacy of drugs⁹. Databases are a crucial medium of cataloging known aspects of drug promiscuity^{10,11}.

The evolution of species through sequence mutations leaves a trail via the conservation of fragments or repeats that have been honed to achieve specific functions with remarkable efficiency¹²⁻¹⁴. The sequence-to-structure-to-function paradigm facilitates the functional characterization of new proteins by applying a 'guilt by association' logic, and has essentially revolutionized the field by its easy to use model¹⁵. However, occasionally nature achieves the same solution to an enzymatic problem through a completely different sequence, arriving at the same spatial conformation required for catalysis^{16,17}. Such convergently evolved proteins, and those redesigned from chiseled scaffolds through exon shuffling, remain beyond the scope of sequence analysis methods. As such structure-based methods have evolved to detect such relationships^{18,19}. We have demonstrated that such a structural conservation leading to the same function necessitates the conservation of electrostatic properties as well (CLASP - www.sanchak.com/clasp)²⁰. The ability of finite difference methods to quickly obtain consistent electrostatic properties from peptide structures provides an invaluable tool for investigating other innate properties of protein structures²¹. Furthermore, using a database of known active sites in proteins (<http://www.ebi.ac.uk/thornton-srv/databases/CSA/>)²², we have proposed a methodology to quantify promiscuity in a wide range of proteins²³.

In an endeavor to establish the validity of the computational predictions made by CLASP, we have undertaken several *in vitro* initiatives using different enzymes. The results of these experiments have provided several insights regarding promiscuous functions in proteins. Foremost amongst them is corroboration of the intuitive notion that inhibition is inherently simpler to predict than true catalysis. For example, we detected the presence of the serine protease (SPASE) catalytic triad motif (Ser195, His57, Asp102) in alkaline phosphatases (AP) from various organisms using the spatial and electrostatic congruence, and validated this by inhibition of the native phosphatase activity using serine protease inhibitors (AEBSF/PMSF)²⁰. However, true SPASE activity was limited to shrimp AP. Recently, the crown domain in the *Escherichia coli* expressed rat intestinal AP protein was shown to be prone to protease cleavage, which the authors have ascribed to self-cleavage²⁴. Another recent review nicely summarizes the various computational approaches applied to the AP superfamily in order to gain insights into the promiscuous functions observed in proteins belonging to the superfamily²⁵. The therapeutic potential of AP inhibitors has also seen increased interest from medicinal researchers²⁶.

In a similar experiment, we detected a SPASE motif in a phosphoinositide-specific phospholipase C (PI-PLC) from *Bacillus cereus* using CLASP²⁷. Once again, although we easily established the inhibition of the native activity of PI-PLC using serine protease inhibitors, we struggled to establish proteolysis based on known protease substrates. Fortuitously, we observed protease activity of PI-PLC on UVI31+, a protein under investigation in our group for different reasons²⁸. We thus concluded that one should exert caution before ruling out protease activity in an enzyme since theoretically proteases have unenumerable number of possible substrates due to the infinite possible DNA sequences that can result in proteins and their corresponding infinite folds²⁷. Thus, it is possible that we have not found the correct proteolytic substrate for APs²⁰.

We also tested the proteolytic functions and inhibition using protease inhibitors of the non-toxic *B. cereus* phosphatidylcholine-specific phospholipase C (PC-PLC) and the closely related highly toxic *Clostridium perfringens* α -toxin (CPA) (which possesses an additional C-terminal domain demonstrated to be responsible for its sphingomyelinase, hemolytic, and lethal activities^{29,30}). CPA and PC-PLC activities on phospholipids were unaffected by the addition of serine protease inhibitors in concurrence with the CLASP analysis which fails to detect a SPASE scaffold in these proteins²⁷. While CPA and PC-PLC did have a metallo-protease motif based on CLASP analysis, and both showed protease activity *in vitro*, the observed proteolytic activity can be attributed as an artifact of a metallo-protease contamination which is difficult to remove in spite of the purification steps. Inhibition of CPA activity using a metallo-protease inhibitor was tried out, but failed to show any results. Such lack of inhibition by a single compound is not sufficient ground to rule out the existence of a metallo-protease scaffold.

Based on predictions from CLASP, we also demonstrated the inhibition of the native phosphatase activity of a cold active alkaline phosphatase from *Vibrio* strain G15-21 AP (VAP)³¹ by a specific β -lactam compound (only imipenem, and not by ertapenem, meropenem, ampicillin or penicillin G)³². CLASP analysis detected a spatial and electrostatic congruence of the active site of a Class B2 CphA metallo- β -lactamase (MBL) from *Aeromonas hydrophila*³³ to the active site of VAP. Several β -lactam compounds failed to inhibit *E. coli* or shrimp AP, as was expected by the lower congruence indicated by CLASP. While all APs contain three metal ion binding sites essential for catalysis³¹, MBLs have either one or two metal binding sites³⁴. It would be interesting to imagine the existence of a protein (possibly evolved from VAP) that is an MBL and requires three metal binding sites.

Another desired aspect in the search of promiscuous motifs is the ability to search for partial scaffolds, as has been implemented in the DECAAF methodology^{35,36}. The search for an elastase-like motif in a plant protein led us to the pathogenesis-related protein P14a³⁷. Although the complete motif was missing - stated previously as, 'While Ser195, His57, and Gly193 from the input motif have a highly matching scaffold in P14a, the spatial position of the elastase Asp102 is close to Asn35 and Ser39 in P14a when the proteins are superimposed based on the matching scaffolds³⁶' - the

Table 1. Non-triviality of the potential and spatial congruence of the active site residues in proteins from the serine protease motif. The reasonably large tyrosine phosphatase CD45 (PDBid: 1YGR, sequence length 610) does not contain the spatially congruent catalytic triad. Although, a motif spatially congruent to the catalytic triad is present in the human translation initiation factor (PDBid: 2E9H), it lacks electrostatic potential congruence. D = Pairwise distance in Å. PD = Pairwise potential difference. SLen = sequence length. APBS writes out the electrostatic potential in dimensionless units of kT/e where k is Boltzmann's constant, T is the temperature in K and e is the charge of an electron.

PDB	Active site atoms(a,b,c)		ab	ac	bc	SLen
1A0J	SER195OG,HIS57NE2,ASP102OD1	D PD	3.3 183.7	7.8 153.2	5.6 -30.4	223
1YGR	SER1101OG,HIS1041NE2,ASP1043OD1	D PD	6.7 -385.2	13.1 -341.0	7.1 44.1	610
2E9H	SER128OG,HIS117NE2,ASP115OD1	D PD	2.9 -44.3	7.1 191.6	6.8 235.9	197

structural similarity of the P14a protein to a snake venom protein with a known elastase function³⁸ suggested strongly the possibility of pre-existing elastase functionality, or indicated a fair chance of endowing elastase activity through directed evolution techniques.

It might appear that the presence of a motif like a SPASE catalytic triad in a protein structure is trivial, and one could expect any randomly chosen protein with a large number of residues to have such a structural motif. However, the absence of a spatially congruent SPASE catalytic triad in a reasonably large tyrosine phosphatase CD45 (PDBid: 1YGR, sequence length 610) highlights the fact that the SPASE motif is not present ubiquitously (Table 1). Even the presence of a spatially congruent motif, as in the human translation initiation factor (PDBid: 2E9H), does not imply potential congruence (Table 1).

The biggest challenge in detecting promiscuous motifs is to be able to endow the function using rational steps^{39–41}. However, the non-additive nature of active site residues makes this a non-trivial task even when a very close partial match exists⁴². For example in a catalytic site consisting of n residues, the existence of a congruent $n - 1$ motif does not imply that it is easy or even possible to add another residue in the structure and obtain the n residue motif. This complexity is best exemplified in the failure to induce β -lactamase activity in a penicillin-binding protein (PBP-5) from *E. coli*^{43,44} by generating the L153E mutant of this protein, as proposed by our previous analysis³⁵ (and unpublished results). Although many

directed evolution experiments have tried to enhance deacylation in PBPs^{45,46}, the catalytic step that β -lactamases use to hydrolyze β -lactams⁴⁷, very few have been successful. Even the successful attempts have reported low gains in β -lactamase activity (110-fold in Chesnel *et al.*⁴⁵ and 90-fold in Urbach *et al.*⁴⁶).

In spite of the inherent difficulty in rationally designing proteins, we believe that the fast maturing field of protein structure prediction might soon allow us to quickly iterate over *in silico* mutations⁴⁸. A method like CLASP may be used to discriminate the predicted structures in order to select the mutations that achieve the desired congruence with a reference scaffold - setting up the flow to mimic the natural 'evolutionary walk' *in vitro*, and accelerate this 'random walk' into a 'resolute sprint'.

Author contributions

All authors contributed equally to the writing, and subsequent refinement, of this commentary.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Jacob F: **Evolution and tinkering**. *Science*. 1977; **196**(4295): 1161–1166. [PubMed Abstract](#) | [Publisher Full Text](#)
- Bone R, Silen JL, Agard DA: **Structural plasticity broadens the specificity of an engineered protease**. *Nature*. 1989; **339**(6221): 191–195. [PubMed Abstract](#) | [Publisher Full Text](#)
- Yoshikuni Y, Ferrin TE, Keasling JD: **Designed divergent evolution of enzyme function**. *Nature*. 2006; **440**(7087): 1078–1082. [PubMed Abstract](#) | [Publisher Full Text](#)
- Khersonsky O, Tawfik DS: **Enzyme promiscuity: a mechanistic and evolutionary perspective**. *Annu Rev Biochem*. 2010; **79**: 471–505. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kimura M: **DNA and the neutral theory**. *Philos Trans R Soc Lond B Biol Sci*. 1986; **312**(1154): 343–354. [PubMed Abstract](#) | [Publisher Full Text](#)
- Amitai G, Gupta RD, Tawfik DS: **Latent evolutionary potentials under the neutral mutational drift of an enzyme**. *HFSP J*. 2007; **1**(1): 67–78. [PubMed Abstract](#) | [Publisher Full Text](#)
- Wroe R, Chan HS, Bornberg-Bauer E: **A structural model of latent evolutionary**

- potentials underlying neutral networks in proteins. *HFSP J.* 2007; 1(1): 79–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Jensen RA: **Enzyme recruitment in evolution of new function.** *Annu Rev Microbiol.* 1976; 30: 409–425.
[PubMed Abstract](#) | [Publisher Full Text](#)
 9. Hu Y, Bajorath J: **High-resolution view of compound promiscuity [v2; ref status: indexed, <http://f1000r.es/t1g>].** *F1000Research.* 2013; 2–144.
[Publisher Full Text](#)
 10. Knox C, Law V, Jewison T, *et al.*: **DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.** *Nucleic Acids Res.* 2011; 39(Database issue): D1035–1041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Gaulton A, Bellis LJ, Bento AP, *et al.*: **ChEMBL: a large-scale bioactivity database for drug discovery.** *Nucleic Acids Res.* 2012; 40(Database issue): D1100–1107.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Wooster R, Bignell G, Lancaster J, *et al.*: **Identification of the breast cancer susceptibility gene BRCA2.** *Nature.* 1995; 378(6559): 789–792.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Preker PJ, Keller W: **The HAT helix, a repetitive motif implicated in RNA processing.** *Trends Biochem Sci.* 1998; 23(1): 15–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Chakraborty S: **A fragmented alignment method detects a putative phosphorylation site and a putative BRC repeat in the *Drosophila melanogaster* BRCA2 protein [v2; ref status: indexed, <http://f1000r.es/1wvc>].** *F1000Research.* 2013; 2–143.
[Publisher Full Text](#)
 15. Altschul SF, Madden TL, Schaffer AA, *et al.*: **Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.** *Nucleic Acids Res.* 1997; 25(17): 3389–3402.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Gherardini PF, Wass MN, Helmer-Citterich M, *et al.*: **Convergent evolution of enzyme active sites is not a rare phenomenon.** *J Mol Biol.* 2007; 372(3): 817–845.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Doolittle RF: **Convergent evolution: the need to be explicit.** *Trends Biochem Sci.* 1994; 19(1): 15–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Russell RB: **Detection of protein three-dimensional side-chain patterns: new examples of convergent evolution.** *J Mol Biol.* 1998; 279(5): 1211–1227.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Kleywegt GJ: **Recognition of spatial motifs in protein structures.** *J Mol Biol.* 1999; 285(4): 1887–1897.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Chakraborty S, Minda R, Salaye L, *et al.*: **Active site detection by spatial conformity and electrostatic analysis-unravelling a proteolytic function in shrimp alkaline phosphatase.** *PLoS One.* 2011; 6(12): e28470.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Baker NA, Sept D, Joseph S, *et al.*: **Electrostatics of nanosystems: application to microtubules and the ribosome.** *Proc Natl Acad Sci U S A.* 2001; 98(18): 10037–10041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Porter CT, Bartlett GJ, Thornton JM: **The Catalytic Site Atlas: a resource of catalytic sites and residues identified in enzymes using structural data.** *Nucleic Acids Res.* 2004; 32(Database issue): D129–133.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Chakraborty S, Rao BJ: **A measure of the promiscuity of proteins and characteristics of residues in the vicinity of the catalytic site that regulate promiscuity.** *PLoS One.* 2012; 7(2): e32011.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Ghosh K, Mazumder Tagore D, Anumula R, *et al.*: **Crystal structure of rat intestinal alkaline phosphatase - Role of crown domain in mammalian alkaline phosphatases.** *J Struct Biol.* 2013; 184(2).
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Duarte F, Amrein BA, Kamerlin SC: **Modeling catalytic promiscuity in the alkaline phosphatase superfamily.** *Phys Chem Chem Phys.* 2013; 15(27): 11160–11177.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Al-Rashida M, Iqbal J: **Therapeutic Potentials of Ecto-Nucleoside Triphosphate Diphosphohydrolase, Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase, Ecto-5'-Nucleotidase, and Alkaline Phosphatase Inhibitors.** *Med Res Rev.* 2013.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Rendon-Ramirez A, Shukla M, Oda M, *et al.*: **A computational module assembled from different protease family motifs identifies PI PLC from *Bacillus cereus* as a putative prolyl peptidase with a serine protease scaffold.** *PLoS One.* 2013; 8(8): e70923.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Shukla M, Minda R, Singh H, *et al.*: **UVI31+ is a DNA endonuclease that dynamically localizes to chloroplast pyrenoids in *C. reinhardtii*.** *PLoS One.* 2012; 7(12): e51913.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Titball RW, Leslie DL, Harvey S, *et al.*: **Hemolytic and sphingomyelinase activities of *Clostridium perfringens* alpha-toxin are dependent on a domain homologous to that of an enzyme from the human arachidonic acid pathway.** *Infect Immun.* 1991; 59(5): 1872–1874.
[PubMed Abstract](#) | [Free Full Text](#)
 30. Sakurai J, Nagahama M, Oda M: ***Clostridium perfringens* alpha-toxin: characterization and mode of action.** *J Biochem.* 2004; 136(5): 569–574.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Helland R, Larsen RL, Asgeirsson B: **The 1.4 Å crystal structure of the large and cold-active *Vibrio* sp. alkaline phosphatase.** *Biochim Biophys Acta.* 2009; 1794(2): 297–308.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Chakraborty S, Asgeirsson B, Minda R, *et al.*: **Inhibition of a cold-active alkaline phosphatase by imipenem revealed by in silico modeling of metallo- β -lactamase active sites.** *FEBS Lett.* 2012; 586(20): 3710–3715.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Garau G, Bebrone C, Anne C, *et al.*: **A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem.** *J Mol Biol.* 2005; 345(4): 785–795.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Bebrone C: **Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily.** *Biochem Pharmacol.* 2007; 74(12): 1686–1701.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Chakraborty S: **An automated flow for directed evolution based on detection of promiscuous scaffolds using spatial and electrostatic properties of catalytic residues.** *PLoS One.* 2012; 7(7): e40408.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Chakraborty S, Minda R, Salaye L, *et al.*: **Promiscuity-based enzyme selection for rational directed evolution experiments.** *Methods Mol Biol.* 2013; 978: 205–216.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Fernandez C, Szyperski T, Bruyere T, *et al.*: **NMR solution structure of the pathogenesis-related protein P14a.** *J Mol Biol.* 1997; 266(3): 576–593.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Bernick JJ, Simpson W: **Distribution of elastase-like enzyme activity among snake venoms.** *Comp Biochem Physiol B.* 1976; 54(1): 51–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Dalby PA: **Strategy and success for the directed evolution of enzymes.** *Curr Opin Struct Biol.* 2011; 21(4): 473–480.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Zanghellini A, Jiang L, Wollacott AM, *et al.*: **New algorithms and an *in silico* benchmark for computational enzyme design.** *Protein Sci.* 2006; 15(12): 2785–2794.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Rothlisberger D, Khersonsky O, Wollacott AM, *et al.*: **Kemp elimination catalysts by computational enzyme design.** *Nature.* 2008; 453(7192): 190–195.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Tokuriki N, Jackson CJ, Afriat-Jumou L, *et al.*: **Diminishing returns and tradeoffs constrain the laboratory optimization of an enzyme.** *Nat Commun.* 2012; 3: 1257.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Nicholas RA, Krings S, Tomberg J, *et al.*: **Crystal structure of wild-type penicillin-binding protein 5 from *Escherichia coli*: implications for deacylation of the acyl-enzyme complex.** *J Biol Chem.* 2003; 278(52): 52826–52833.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Sarkar SK, Dutta M, Chowdhury C, *et al.*: **PBP5, PBP6 and DacD play different roles in intrinsic β -lactam resistance of *Escherichia coli*.** *Microbiology.* 2011; 157(Pt 9): 2702–2707.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Chesnel L, Zapun A, Mouz N, *et al.*: **Increase of the deacylation rate of PBP2x from *Streptococcus pneumoniae* by single point mutations mimicking the class A beta-lactamases.** *Eur J Biochem.* 2002; 269(6): 1678–1683.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Urbach C, Evrard C, Pudzaitis V, *et al.*: **Structure of PBP-A from *Thermosynechococcus elongatus*, a penicillin-binding protein closely related to class A beta-lactamases.** *J Mol Biol.* 2009; 386(1): 109–120.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Matagne A, Lamotte-Brasseur J, Frere JM: **Catalytic properties of class A β -lactamases: efficiency and diversity.** *Biochem J.* 1998; 330(Pt 2): 581–598.
[PubMed Abstract](#) | [Free Full Text](#)
 48. Zhang Y: **Progress and challenges in protein structure prediction.** *Curr Opin Struct Biol.* 2008; 18(3): 342–348.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 07 January 2014

<https://doi.org/10.5256/f1000research.2917.r2833>

© 2014 Nath A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abhinav Nath

Department of Molecular Biophysics & Biochemistry, Yale University, New Haven CT, USA

The commentary by Chakraborty *et al.* focuses on the important topics of understanding and modeling enzyme promiscuity, and raises some intriguing points about the importance of local electrostatic effects (beyond structure alone) on enzyme activity. However, the commentary is quite tightly focused on protease-type activity in different scaffolds, and even more so on the authors' own work. This manuscript would be improved by providing more context on how their previous work relates to other studies of AP promiscuity/polyspecificity (including in particular the work of the Herschlag and Hollfelder groups) and electrostatic approaches to enzyme mechanism (Warshel, Houk, and many others). This would broaden the potential audience for this commentary, which as it stands is rather narrow.

Moving on to specifics, I am unconvinced by the use of protease inhibitors as a test of *bona fide* protease activity in several of the works discussed. The fact that a particular compound inhibits an enzyme does not necessarily mean that it resembles a substrate, or that the enzyme's mode of action resembles that of the compound's other targets. On the other hand, as the authors acknowledge, the absence of inhibition by a particular compound is not enough to demonstrate the lack of a particular activity or functional motif. These assays thus have significant risks of both false positives and false negatives, and these should be explicitly discussed. What we are left with are apparently observations of protease activity both by enzymes predicted to have SPASE activity (shrimp and *E. coli* APs, and PI-PLC) and by those predicted to lack it (PC-PLC and CPA) – unfortunately, not very strong evidence for the power of their approach. The authors should discuss these issues and their potential solutions.

In Table 1, it is not clear what 1A0J is. Also, it is not clear what the criteria are for either spatial or potential congruence. More broadly, it is difficult to assess the frequency of SPASE-compatible triads in proteins in general from just 3 examples. Is it feasible for the authors to estimate the frequency of spatial and potential congruence in a larger set of protein structures (or even the entire PDB)?

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Jan 2014

Sandeep Chakraborty, Tata Institute of Fundamental Research, Mumbai, India

Dear Dr Nath,

We would like to thank you for taking the time to review our manuscript. We have responded in detail to another review by Dr Rawlings, and an updated version of our manuscript has now been published. We hope our dialogue with Dr Rawlings will provide more clarity on our work. For the sake of brevity, we have not repeated several aspects that we have pointed out there. Please find our detailed responses to your comments below.

The commentary by Chakraborty *et al.* focuses on the important topics of understanding and modeling enzyme promiscuity, and raises some intriguing points about the importance of local electrostatic effects (beyond structure alone) on enzyme activity. However, the commentary is quite tightly focused on protease-type activity in different scaffolds, and even more so on the authors own work. This manuscript would be improved by providing more context on how their previous work relates to other studies of AP promiscuity/polyspecificity (including in particular the work of the Herschlag and Hollfelder groups) and electrostatic approaches to enzyme mechanism (Warshel, Houk, and many others). This would broaden the potential audience for this commentary, which as it stands is rather narrow.

We appreciate your encouraging comments on the importance of the field of our work. We would like to emphasize that we have also worked on β -lactamases apart from proteases - and are currently working on proteins with other enzymatic activities as well (lipases, sulfatases, etc.).

We have mentioned that we intend this commentary to focus exclusively on our work (and any novel aspects we might have unraveled), and not the work of previous researchers on whose results we have built our research - thus, we have kept this as a commentary, and not a review. We have discussed previous studies in each of our papers separately - for example, the field of quantum, classical, and statistical techniques that have evolved in the last few decades (involving Karplus, Levitt, Warshel, Herschlag and many others) has been discussed in detail in Chakraborty S (2013) A Quantitative Measure of Electrostatic Perturbation in Holo and Apo Enzymes Induced by Structural Changes. *PLoS ONE* 8(3): e59352. doi:10.1371/journal.pone.0059352.

Moving on to specifics, I am unconvinced by the use of protease inhibitors as a test of bona fide protease activity in several of the works discussed. The fact that a particular compound inhibits an enzyme does not necessarily mean that it resembles a substrate, or that the enzymes mode of action resembles that of the compounds other targets.

We agree that inhibition does not *"not necessarily mean that it resembles a substrate, or that the enzymes mode of action resembles that of the compounds other targets"*. However, given the *in silico* demonstration of the congruence of the new scaffold to existing ones with known function, it does add credence to the hypothesis. Further, we have confirmation from other groups (unknown to us) that a recombinant AP does have self proteolytic function - they cite our work in order to rationalize this result [37].

On the other hand, as the authors acknowledge, the absence of inhibition by a particular compound is not enough to demonstrate the lack of a particular activity or functional motif. These assays thus have significant risks of both false positives and false negatives, and these should be explicitly discussed.

This is something we should touch upon. We thank you for pointing this out.

What we are left with are apparently observations of protease activity both by enzymes predicted to have SPASE activity (shrimp and E. coli APs, and PI-PLC) and by those predicted to lack it (PC-PLC and CPA) unfortunately, not very strong evidence for the power of their approach. The authors should discuss these issues and their potential solutions.

We do see protease activity in PC-PLC and CPA - however, it is impossible to remove protease contamination, and thus we cannot ascribe it to the protein. This is not a negative result for us - it is just a result we cannot confirm under current constraints of protein purification, and thus we cannot (and have not) used it to forward our hypothesis.

In Table 1, it is not clear what 1A0J is.

We have fixed this in version 2 (the other reviewer has pointed this out too).

Also, it is not clear what the criteria are for either spatial or potential congruence. More broadly, it is difficult to assess the frequency of SPASE-compatible triads in proteins in general from just 3 examples. Is it feasible for the authors to estimate the frequency of spatial and potential congruence in a larger set of protein structures (or even the entire PDB)?

We have done something like this in a recently published work where we show the inhibition of PI-PLC using dpp4 inhibitors that are used in type 2 diabetes therapy - <http://f1000research.com/articles/2-286>. A comprehensive set of 5000 human proteins has been queried using SPASE like motifs, and the significant results have been seen to be small in comparison to the number of proteins queried. For example, using a four residue motif from trypsin we find only 1% of proteins (about 50 proteins) that have significantly congruent active site motifs (considering both spatial and electrostatic properties).

We appreciate the reservations you have, and we share some of the concerns as we strive to establish our work in a collaborative effort. We hope you will find our arguments compelling enough to accept our manuscript.

Best regards,

Sandeep Chakraborty

Competing Interests: No competing interests were disclosed.

Reviewer Report 20 December 2013

<https://doi.org/10.5256/f1000research.2917.r2636>

© 2013 Rawlings N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neil D. Rawlings

Wellcome Trust Genome Campus, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK

This commentary reads more like a review and only describes work previously performed by the researchers. I have a number of reservations about this previously published work. The authors should present more detail from at least one example where dual activity has been proven.

Some of the claims made by the authors are extraordinary. Can the authors supply any explanation for the presence of a serine peptidase activity in alkaline phosphatase from a shrimp, but not *Escherichia coli*? If there was any physiological relevance for the peptidase activity for an alkaline phosphatase then surely it would be conserved. It seems extraordinarily serendipitous that the authors are working on UVI31+ and that this is the only substrate for the peptidase activity of shrimp alkaline phosphatase the authors could detect. This is unlikely to be a physiological substrate, which implies that the serine peptidase activity of alkaline phosphatase is very general, and it is behaving as if its' role were protein degradation rather than limited processing.

Given that there are so many other peptidases for recycling proteins - the proteasome in the cytoplasm, lysosomal peptidases, digestive enzymes of the stomach and gut, for example - what would be the evolutionary pressure to maintain such a generalized function for alkaline phosphatase? Have the alleged serine peptidase activity of shrimp alkaline phosphatase, and the alleged inhibition of alkaline phosphatase activity by a serine peptidase inhibitor been confirmed by other researchers? I can understand that a small molecule like PMSF might block any active site serine, regardless of the type of enzyme, but the authors claim that the protein ovoinhibitor reduces alkaline phosphatase activity, which would require not only an active site but also at least one substrate binding site for the reactive site in the inhibitor. Perhaps this is merely some irrelevant, non-specific binding rather than true inhibition.

Why were synthetic substrates not used instead of proteins? Then proper kinetics could be measured, rather than presenting bands on a gel. Clearly the authors are aware of the dangers of contamination, because they admit to having had problems with a metallopeptidase contaminating phospholipase C, for which their CLASP analysis predicts a metallopeptidase-like active site. The controls that the authors use in their experiments, namely to denature all proteins

with SDS, would not address this problem, because any contaminant would be denatured as well as the enzyme under experimentation. Use of peptidase inhibitors would be equally useless if the catalytic type of the contaminating peptidase and the enzyme in question were the same. Perhaps the authors should abandon commercial preparations and use recombinant enzymes where it would be possible to mutate active site residues to show that a knockout abrogates activity?

The authors state that their CLASP analysis is unable to find a serine peptidase-like active site in phospholipase C, and that this is confirmed by failure to inhibit phospholipase C with a serine peptidase inhibitor. This is an example of a negative result proving a negative hypothesis, which really doesn't prove anything.

In Table 1, the structure 1A0J should be described in the legend.

Promiscuity in enzyme active sites is a known phenomenon. An example that comes to mind is leukotriene A4 hydrolase, which not only hydrolyses the epoxide but also acts as an aminopeptidase using the same active site. There are also numerous examples where an active site performs different functions in different organisms (or even in the same organism for some protein products of paralogous genes): for example proteins with the alpha/beta hydrolase fold, where some are peptidases and some are lipases. It would strengthen the authors' case considerably to include examples such as these before discussing their own results.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 16 Jan 2014

Sandeep Chakraborty, Tata Institute of Fundamental Research, Mumbai, India

Dear Dr Rawlings,

We would like to thank you for taking the time to review our manuscript. We appreciate several incisive and relevant points raised by you, and hope that our arguments are convincing enough for you to change your opinion about our work. There are two aspects of our work that need to be dissected separately.

STAGE1: The first stage establishes the presence of active site scaffolds (for example, the serine protease catalytic triad) through:

(a) spatial congruence (a method devised previously [29, 30]).

(b) electrostatic congruence of cognate pairs of active site residues in proteins with the same function - our original contribution.

STAGE2: In the next stage, we have attempted to correlate our *in silico* findings through *in vitro* experiments. It is salient to note that the results of STAGE1 are not nullified irrespective

of the results in these experiments. However, the results have indeed corroborated our hypothesis in several experiments. Although, as you so aptly point out, there is still work that needs to be done.

Point (b) in STAGE1 might be subject to scrutiny for several reasons:

- (i) The validity and accuracy of finite difference Poisson Boltzmann methods.
- (ii) The non-trivial nature of the electrostatic potential difference.

We have argued in favor of both these points throughout our work. *"This invariance in the electrostatic features (measured in structures that have been solved independently over many years) is an innate property required for the enzymatic activity. This also speaks highly of the reliability of the APBS/PDB2PQR implementation"* [51]. Assuming that (a) and (b) are valid; surely one cannot deny the existence of a scaffold resembling the catalytic triad from subtilisin and trypsin in alkaline phosphatases (Table 3 in [32])?

Please find our detailed responses to your comments below:

This commentary reads more like a review and only describes work previously performed by the researchers. I have a number of reservations about this previously published work. The authors should present more detail from at least one example where dual activity has been proven.

We have explicitly stated in the abstract that we intend to *'discuss insights gained in several initiatives using our method on different enzymes'*. Thus, this would not qualify as a review since we do not consider the work of those researchers whose work we have built upon.

Can the authors supply any explanation for the presence of a serine peptidase activity in alkaline phosphatase from a shrimp, but not *Escherichia coli*? If there was any physiological relevance for the peptidase activity for an alkaline phosphatase then surely it would be conserved. It seems extraordinarily serendipitous that the authors are working on UVI31+ and that this is the only substrate for the peptidase activity of shrimp alkaline phosphatase the authors could detect. This is unlikely to be a physiological substrate, which implies that the serine peptidase activity of alkaline phosphatase is very general, and it is behaving as if its role was protein degradation rather than limited processing. Given that there are so many other peptidases for recycling proteins - the proteasome in the cytoplasm, lysosomal peptidases, digestive enzymes of the stomach and gut, for example - what would be the evolutionary pressure to maintain such a generalized function for alkaline phosphatase? Have the alleged serine peptidase activity of shrimp alkaline phosphatase, and the alleged inhibition of alkaline phosphatase activity by a serine peptidase inhibitor been confirmed by other researchers?

It is precisely these questions that our findings raise - and it would be unfair to put the onus of answering these fundamental questions on the method itself. Fortunately for us, the recent findings of a group working on alkaline phosphatase (and not personally known to us), have shown the presence of auto cleavage in these alkaline phosphatases - *"the loss of crown domain due to protease cleavage could result from self-cleavage of the protein, specifically when metal sites are not fully occupied"* [36]. Citing our work, they have hypothesized on the

physiological relevance of the peptidase activity. Since they use recombinant protein, the danger of contamination is minimal - a point that you have raised below.

It is to be said that we agree that it seems unlikely that there is an evolutionary pressure to maintain a peptidase function in APs, given the plethora of such enzymes that you have pointed out. However, promiscuity often allows functional units (partial or complete) to serendipitously piggyback on the 'real' function being maintained and honed by evolution. It is not the existence of peptidase activity, but the distinct possibility that APs may have some peptidase activity that is of interest. The peptidase-like scaffold in APs might be one such latent functionality - possibly a remnant of a primeval parent protein that duplicated to result into the current serine peptidases and APs (both hydrolases).

Finally, there is precedence of a promiscuous activity that is present in only one of the APs (ECAP) - "*A phosphite-dependent hydrogenase activity was also found in ECAP, but was absent in APs from other organisms [19]*". Another example is the inhibition of VAP using imipenem, which does not inhibit ECAP.

I can understand that a small molecule like PMSF might block any active site serine, regardless of the type of enzyme, but the authors claim that the protein ovoidinhibitor reduces alkaline phosphatase activity, which would require not only an active site but also at least one substrate binding site for the reactive site in the inhibitor. Perhaps this is merely some irrelevant, non-specific binding rather than true inhibition.

We have shown the binding of AEBSF to shrimp alkaline phosphatase through MALDI-mass spectrometry (Fig 4d in [32]).

Why were synthetic substrates not used instead of proteins? Then proper kinetics could be measured, rather than presenting bands on a gel.

We did try out many synthetic substrates, but we could not find any protease activity. However we have not yet tried the Pro-Xxx that would duplicate the bond in UVI31+ cleaved by PI-PLC. We believe that '*one should exert caution before ruling out protease activity in an enzyme since theoretically proteases have an innumerable number of possible substrates due to the infinite possible DNA sequences that can result in proteins and their corresponding infinite folds*', as mentioned in the current commentary. However, I do think we ought to try out prolyl peptidases substrates (and will in the near future).

Clearly the authors are aware of the dangers of contamination, because they admit to having had problems with a metallopeptidase contaminating phospholipase C, for which their CLASP analysis predicts a metallopeptidase-like active site.

Precisely - it would be improper to consider that the metallophospholipase has protease activity as it is difficult to remove the protease contamination, and we have not.

The controls that the authors use in their experiments, namely to denature all proteins with SDS, would not address this problem, because any contaminant would be denatured as well as the enzyme under experimentation. Use of peptidase inhibitors would be equally useless if the catalytic type of the contaminating peptidase and the enzyme in question were the same.

We have not tried to rule out contamination by denaturing the proteins or using inhibitors for the reasons mentioned by you. Could you kindly point out where this might have been mistakenly specified by us?

Perhaps the authors should abandon commercial preparations and use recombinant enzymes where it would be possible to mutate active site residues to show that a knockout abrogates activity?

We agree that recombinant enzymes with a knock out mutation would clinch our argument. However, financial and logistic restrictions make this currently unfeasible (for me on a personal note). Fortunately, the protease activity in a recombinant alkaline phosphatase has been shown by a different group [37].

The authors state that their CLASP analysis is unable to find a serine peptidase-like active site in phospholipase C, and that this is confirmed by failure to inhibit phospholipase C with a serine peptidase inhibitor. This is an example of a negative result proving a negative hypothesis, which really doesn't prove anything.

There has been some misunderstanding - we mention '*CPA and PC-PLC activities on phospholipids were unaffected by the addition of serine protease inhibitors in concurrence with the CLASP analysis which fails to detect a SPASE scaffold in these proteins*'. This is expected, since they are metallo proteins. CLASP does find the serine peptidase-like active site in PI-PLC, which we go on to confirm through in vitro experiments [39].

In Table 1, the structure 1A0J should be described in the legend.

We have made the correction, thank you.

Promiscuity in enzyme active sites is a known phenomenon. An example that comes to mind is leukotriene A4 hydrolase, which not only hydrolyses the epoxide but also acts as an aminopeptidase using the same active site. There are also numerous examples where an active site performs different functions in different organisms (or even in the same organism for some protein products of paralogous genes): for example proteins with the alpha/beta hydrolase fold, where some are peptidases and some are lipases. It would strengthen the authors' case considerably to include examples such as these before discussing their own results.

We acknowledge that promiscuity in enzymes has been a phenomenon that has been established over the last couple of decades by several researchers. In accordance with your suggestion, we have added a brief discussion of promiscuous enzymes and related work. Our contribution, we think, has been to formalize computational methods that facilitate the search for latent promiscuous scaffolds in the active site of proteins, and increase the specificity of matches by introducing a filtering in the form of electrostatic potential congruence. In this endeavor, we believe, we have further strengthened the previously hypothesized key role that promiscuity plays in the evolution of proteins [7].

We hope you will find our arguments compelling enough to accept our manuscript. Once again, we thank you for your valuable comments as we strive to establish our work in a collaborative effort.

Best regards,

Sandeep Chakraborty

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research